Genentech, Inc.

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This early-stage trial tests an experimental drug called RO7823653, given as an eye injection alone or with an approved drug (faricimab), for people with diabetic macular edema—a condition where diabetes causes fluid buildup and vision loss in the center of the eye. The study wil…

This study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The m…

This study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…

This study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This study is testing a refillable eye implant that delivers the drug ranibizumab to treat wet age-related macular degeneration (AMD). The main goal is to see if the implant affects the cells on the inner surface of the cornea. About 188 people with wet AMD will receive the impla…

This study tests a new drug called GDC-4198, alone or combined with another drug (giredestrant), against a standard treatment (abemaciclib plus giredestrant) in people with advanced ER+/HER2- breast cancer that has worsened after prior CDK4/6 inhibitor therapy. The trial has two …

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves…

This early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…

This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…

This Phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) and an immunotherapy drug (atezolizumab) to standard chemotherapy (mFOLFIRINOX) can keep pancreatic cancer from coming back after surgery. About 260 people whose tumors were completely remo…

This study tests a drug called selnoflast in 162 people with atherosclerosis (hardened arteries) who are at high risk for heart attacks or strokes. The goal is to see if selnoflast can reduce inflammation inside the arteries, measured by a special PET scan, compared to a placebo.…

This study tests a new drug called RO7837195 for people with moderate to severe ulcerative colitis who haven't gotten better with other treatments. About 224 participants will receive either the drug or a placebo for 12 weeks to see if it can bring about remission. The goal is to…

This study tests a new drug called GDC-7035, designed to target cancers with a specific genetic change called KRAS G12D. The trial includes about 410 adults with advanced solid tumors that have not responded to other treatments. Researchers will give the drug alone or with other …

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …

This expanded access program provides giredestrant, a daily oral drug, to people with ER-positive, HER2-negative breast cancer (early or advanced) who have limited treatment options. The goal is to offer early access before the drug is commercially available in the US. Participan…

This early-stage study tests an inhaled drug called GDC-6988 in people with lung conditions that cause thick mucus, like non-CF bronchiectasis and COPD. The main goal is to check if the drug is safe and tolerable. About 128 adults with stable disease and good lung function will t…

This registry follows pregnant women who have taken mycophenolate, a drug used to prevent organ rejection and treat autoimmune diseases. Researchers will collect data on pregnancy complications and birth defects up to one year after birth. The goal is to better understand the dru…

This early-phase study looks at how a single dose of the drug inavolisib behaves in people with moderate or severe liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver pro…

This early-stage trial is testing a new drug called RO7875913 in 40 healthy volunteers to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo. The study aims to find the right dose for future trials, but offers no direct treatme…